
Auna (NYSE:AUNA) reported 10% foreign-exchange-neutral revenue growth for the third quarter of 2026, but profitability came under pressure from an oncology contract in Colombia and prior-period billing adjustments in Peru, executives said on the company’s earnings call.
Mexico provided a counterweight, recording its first year-over-year increase in adjusted EBITDA in 2026 as surgical and oncology volumes rose. The company also reported stronger cash generation and reiterated its full-year revenue growth guidance, while expecting adjusted EBITDA to be broadly stable or slightly lower than in 2025.
Colombia Contract and Price Caps Weigh on Results
The contract, which accounted for approximately 4% of Colombia revenue and covered about 500,000 lives, experienced a higher-than-expected incidence of advanced-stage cancer. Auna terminated the agreement and engaged legal counsel to review recovery options, Zamora said.
Chief Financial Officer and Executive Vice President Gisele Remy estimated that roughly 70% of the $4 million year-over-year decline in Colombia’s quarterly adjusted EBITDA came from the contract, with the remaining 30% attributable to price caps. The caps took effect during the third quarter and will apply throughout the fourth quarter, she said.
Zamora said management did not believe the contract’s problems would spread to the company’s other risk-sharing arrangements. Auna is also working to improve efficiency and adjust its payer and revenue mix in Colombia, where wage increases and a shorter statutory workweek have added to costs.
Mexico Improves as Peru Absorbs Billing Adjustments
Mexico’s adjusted EBITDA rose 5% year over year, while the Monterrey Healthcare Network’s adjusted EBITDA increased 10%, Remy said. Surgery volumes in Mexico rose 12%, and chemotherapy and radiotherapy sessions increased 34%.
Remy said Mexico’s total capacity utilization reached 41%, up 2.9 percentage points. The Monterrey network had an adjusted EBITDA margin of 28% at that occupancy level, she said. Zamora said utilization could increase by two to three percentage points a year as the company seeks to improve margins.
The healthcare network’s growth helped offset weaker results at Auna Seguros, which faced industrywide pressure from changes to VAT deductibility in Mexico’s insurance market, executives said.
In Peru, surgery volumes increased 21%, while chemotherapy and radiotherapy sessions rose 18%. Nevertheless, Peru adjusted EBITDA fell 6%, as the company recorded PEN 18 million in revenue adjustments, primarily tied to prior-year billing matters. Excluding their net impact, adjusted EBITDA would have been broadly stable, Remy said.
New business-to-business accounts that have not yet reached normal utilization, along with higher pharmacy and clinical payroll expenses, also affected Peru’s profitability. Auna expects to add approximately 4,000 plan members in the fourth quarter through two corporate agreements.
Remy said billing-related effects from previous periods are expected to continue over the coming quarters and normalize toward the second half of 2027.
Cash Flow and Full-Year Outlook
For the first nine months of 2026, net operating cash flow rose 62% to PEN 713 million and free cash flow increased 95% to PEN 626 million. Remy attributed the gains to improved collections, lower receivable days in Peru and Mexico, stable collections in Colombia and lower tax payments.
Auna’s leverage ratio improved sequentially to 3.5 times, moving closer to its medium-term target of three times. The company ended the third quarter with PEN 614 million in cash and just over $134 million available under its credit lines, Remy said.
Management maintained its forecast for 2026 revenue growth of 10% to 14% on an FX-neutral basis and capital expenditure of approximately 4% of consolidated revenue. Remy said the Peru billing issues and Colombia price caps would continue to pressure margins in the fourth quarter, while Mexico’s adjusted EBITDA was expected to keep growing.
Asked about the approximately $100 million remaining on Auna’s 2029 bonds, Remy said the company was evaluating refinancing alternatives. The bonds are callable at the end of 2026 at 105%, she said.
About Auna (NYSE:AUNA)
Auna S.A. is a Latin American healthcare company that provides medical care through a network of hospitals, clinics and specialized treatment centers. Its services include general and specialty care, diagnostic services and cancer treatment. The company also offers health plans and other healthcare financing services, integrating coverage with care delivery. Auna serves patients in Peru, Colombia and Mexico.
